Samil Pharmaceutical Co.,Ltd

A000520

KR7000520007

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-26 EDT			5-day change	1st Jan Change
8,170 ^KRW	-0.97%		-11.68%	+21.94%

03-14	Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 30, 2021.

November 28, 2022 at 09:03 pm

From October 1, 2022 to November 29, 2022, the company has repurchased 0 shares, representing 0% for KRW 0 million. With this, the company has completed the repurchase of 125,939 shares, representing 0.99% for KRW 997.71 million under the buyback announced on November 30, 2021.

Latest news about Samil Pharmaceutical Co.,Ltd

Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
Samil Pharmaceutical Co.,Ltd announced that it has received KRW 12 billion in funding	23-04-18	CI
Samil Pharmaceutical Co.,Ltd announced that it expects to receive KRW 12 billion in funding	23-04-16	CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 30, 2021.	22-11-28	CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 30, 2021.	22-11-28	CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 30, 2021.	22-11-28	CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on November 30, 2021.	22-11-28	CI
Samil Pharmaceutical Co.,Ltd's Equity Buyback announced on November 30, 2021, has expired with 125,939 shares, representing 0.99% for KRW 997.71 million.	22-11-28	CI
Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on October 5, 2021.	22-10-06	CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on October 5, 2021.	22-10-06	CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on October 5, 2021.	22-10-06	CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on October 5, 2021.	22-10-06	CI
Samil Pharmaceutical Co.,Ltd's Equity Buyback announced on October 5, 2021, has expired with 119,560 shares, representing 0.94% for KRW 996.5 million.	22-10-03	CI
Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Samil Pharmaceutical Co.,Ltd announced that it has received KRW 4 billion in funding	22-07-27	CI
Samil Pharmaceutical Co.,Ltd announced that it has received KRW 5 billion in funding	22-07-27	CI
Samil Pharmaceutical Co.,Ltd announced that it expects to receive KRW 4 billion in funding	22-07-25	CI
Samil Pharmaceutical Co.,Ltd announced that it expects to receive KRW 5 billion in funding	22-07-25	CI
Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-08	CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on April 30, 2021.	22-05-03	CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on April 30, 2021.	22-05-03	CI
Tranche Update on Samil Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on April 30, 2021.	22-05-03	CI

Chart Samil Pharmaceutical Co.,Ltd

Duration

Period

More charts

Company Profile

SAMIL PHARMACEUTICAL CO., LTD is a Korea-based company mainly engaged in the manufacture of medicines. The Companyâs products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The Company distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.

Sector

Pharmaceuticals

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SAMIL PHARMACEUTICAL CO.,LTD	+21.94%	122M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+16.40%	42.95B
OTSUKA HOLDINGS CO., LTD.	+16.32%	21.38B
SANDOZ GROUP AG	+20.14%	15.05B
CIPLA LIMITED	+18.64%	14.45B
ZYDUS LIFESCIENCES LIMITED	+53.58%	13.04B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.64%	6.72B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+11.21%	5.47B